Kewaunee Scienti - KEQU STOCK NEWS

Kewaunee Scientific (NASDAQ: KEQU) reported its Q3 FY2025 results with sales of $67.17 million, up 43.6% year-over-year. However, pre-tax earnings decreased 63.7% to $1.28 million, with diluted EPS falling to $0.45 from $0.85.

The quarter included costs related to the Nu Aire acquisition, completed on November 1, 2024. Adjusting for acquisition and integration costs of $2.51 million, adjusted pre-tax earnings were $3.79 million, up 7.8% YoY, with adjusted EPS of $1.09.

Key metrics include:

• Order backlog: $221.6 million (up from $152.3 million YoY)
• Domestic sales: $51.98 million (+63.6% YoY)
• International sales: $15.19 million (+1.2% YoY)
• Cash position: $12.34 million
• Debt-to-equity ratio: 1.29-to-1

The company's Domestic segment showed strong performance, while the International segment faced challenges due to customer site delays. Management remains focused on operational excellence and strategic growth initiatives.

Kewaunee Scientific (NASDAQ: KEQU) has announced it will release its third quarter fiscal year 2025 financial results on March 12, 2025 after market close. The results will be available on the company's website.

Founded in 1906, Kewaunee Scientific is a global leader in laboratory, healthcare, and technical furniture products manufacturing. The company operates manufacturing facilities in Statesville, North Carolina, and Bangalore, India. Through its recently acquired subsidiary Nu Aire, founded in 1971, the company has expanded its portfolio to include biological safety cabinets, CO2 incubators, and ultralow freezers. Nu Aire's facilities are located in Plymouth and Long Lake, Minnesota.

Kewaunee Scientific (NASDAQ: KEQU) reported Q2 FY2025 results with sales of $47.76M, down 5.3% YoY. Pre-tax earnings decreased 18.9% to $3.93M, while net earnings increased to $3.01M from $2.73M. The company's order backlog reached a historic high of $184.4M.

Domestic segment sales grew 6.5% to $36.41M, while International segment sales declined 30.1% to $11.36M due to construction delays in India. The company maintained strong liquidity with $29.66M cash on hand and reduced its debt-to-equity ratio to 0.59-to-1.

On November 1, 2024, Kewaunee completed the acquisition of Nu Aire, Inc., a leading manufacturer of biological safety cabinets and airflow products, incurring $2.3M in acquisition-related expenses during the quarter.

Kewaunee Scientific (NASDAQ: KEQU) announced it will release its second quarter fiscal year 2025 financial results on Wednesday, December 11, 2024 after market close. The results will be available on the company's website. Kewaunee Scientific, founded in 1906, is a global leader in laboratory, healthcare, and technical furniture products manufacturing, with headquarters in Statesville, North Carolina and manufacturing facilities in the US and India.

Kewaunee Scientific (NASDAQ: KEQU) has completed the acquisition of Nu Aire, a Minneapolis-based manufacturer of laboratory equipment, for $55 million. Nu Aire specializes in biological safety cabinets, airflow products, CO2 incubators, and related equipment serving life sciences, healthcare, and education sectors. The acquisition expands Kewaunee's product portfolio and market reach through Nu Aire's established distribution network. Bill Peters will continue as Nu Aire's President and join Kewaunee's corporate management team. The combined organization aims to enhance product offerings and leverage operational synergies for improved performance and sustainable growth.

Kewaunee Scientific (NASDAQ: KEQU) reported its Q1 FY2025 results. Key highlights include:

- Sales decreased 2.9% to $48,393,000
- Pre-tax earnings fell 28.8% to $2,430,000
- Net earnings decreased to $2,193,000
- Diluted EPS dropped to $0.74 from $0.86
- Order backlog increased to $159.4 million
- Domestic sales rose 0.3% to $35,523,000
- International sales declined 10.7% to $12,870,000

The company maintained a strong financial position with $25,186,000 in cash and a debt-to-equity ratio of 0.68-to-1. Despite challenges in the international segment due to project delays in India, the domestic segment showed improved performance. The company's CEO expressed confidence in another strong year based on the robust backlog and high quoting activity.

Kewaunee Scientific (NASDAQ: KEQU), a global leader in laboratory, healthcare, and technical furniture products, announces its participation in the 2024 Arablab Live tradeshow in Dubai from September 24-26. The event will host industry professionals from over 120 countries, showcasing innovations in life sciences, clean energy, industrial, and chemical sectors.

Kewaunee's executive and sales teams will be present at Hall 3, Stand 708 of the Dubai World Trade Centre, offering product demonstrations and networking opportunities. The company aims to connect with international partners, exchange knowledge, and highlight its innovative solutions for laboratory spaces worldwide.

Kewaunee Scientific (NASDAQ: KEQU) has announced plans to release its first quarter fiscal year 2025 financial results on Wednesday, September 11, 2024, after the close of trading. The information will be available on the company's website following the release.

Kewaunee Scientific, founded in 1906, is a global leader in designing, manufacturing, and installing laboratory, healthcare, and technical furniture products. The company's product range includes steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.

Headquartered in Statesville, North Carolina, Kewaunee Scientific has sales offices in the United States, India, Saudi Arabia, and Singapore. It operates three manufacturing facilities in Statesville and one in Bangalore, India, serving domestic and international markets.

Kewaunee Scientific announced its fiscal year and fourth quarter results for the period ending April 30, 2024. Fourth quarter sales increased by 5% to $56.7 million, with adjusted net earnings rising to $4.6 million from $1 million year-over-year. Adjusted diluted earnings per share for the quarter were $1.55, up from $0.34. For the fiscal year, sales dropped by 7.2% to $203.8 million, while adjusted net earnings surged to $12.3 million from $738,000. Adjusted EBITDA for the fiscal year was $20.7 million, up from $7.5 million. The order backlog rose to $155.6 million. The company also noted two significant non-recurring transactions: the annuitization of its pension obligations and the reversal of a valuation allowance, impacting earnings and EBITDA.